Compare FBK & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FBK | ARQT |
|---|---|---|
| Founded | 1906 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2016 | 2020 |
| Metric | FBK | ARQT |
|---|---|---|
| Price | $55.02 | $24.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $62.75 | $34.00 |
| AVG Volume (30 Days) | 283.7K | ★ 1.1M |
| Earning Date | 04-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.49% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ 2.45 | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $43.54 | $34.46 |
| Revenue Next Year | $7.86 | $29.77 |
| P/E Ratio | $23.04 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $39.47 | $12.42 |
| 52 Week High | $62.37 | $31.77 |
| Indicator | FBK | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 59.01 | 52.71 |
| Support Level | $51.79 | $22.56 |
| Resistance Level | $56.30 | $25.03 |
| Average True Range (ATR) | 1.14 | 0.96 |
| MACD | 0.69 | 0.35 |
| Stochastic Oscillator | 72.98 | 77.75 |
FB Financial Corp is a bank holding company. The company through its wholly-owned bank subsidiary provides commercial and consumer banking services to clients in select markets in Tennessee, North Alabama, and North Georgia. The company segment includes Banking and Mortgage. It generates majority of revenue from the Banking segment which provides a full range of deposit and lending products and services to corporate, commercial, and consumer customers. The Mortgage segment includes the servicing of residential mortgage loans and the packaging and securitization of loans to governmental agencies.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.